Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • stockvadar stockvadar Aug 24, 2013 8:41 PM Flag

    Why Belviq Refills Are Out-Pacing Qsymia, I'll explain. Stockvadar-offers

    Investors. To explain how Belviq (B) has overtaken Qsymia's (Q) refill growth, I'll explain. Starting with 6/14/13, watch the growth pace wk/wk of refills ONLY for the last 10 weeks (why I use 10 weeks is for a direct comparison between Belviq vs Qsymia).

    6/7/13..................Q=1169
    6/14/13 B=6 (0 growth) vs Q=1812 (+643 growth)
    6/21/13 B=58 (+52 growth) vs Q=1262 (-550 loss)
    6/28/12 B=104 (+46 growth) vs Q=1205 (-57 loss)
    7/5/13 B=146 (+42 growth) vs Q=1204 (-1 loss)
    7/12/13 B=249 (+103 growth) vs Q=1281 (+77 growth)
    7/19/13 B=343 (+94 growth) vs Q=1325 (+44 growth)
    7/26/13 B=380 (+37 growth) vs Q=1313 (-12 loss)
    8/2/13 B=458 (+78 growth) vs Q=1512 (+199 growth)
    8/9/13 B=454 (-4 loss) vs Q=1378 (-134 loss)
    8/16/13 B=528 (+74 growth) vs Q=1510 (+132 growth)

    Starting 6/14/13, Belviq growth = Refills total +522 over 10 weeks
    Starting 6/14/13, Qsymia growth = Refills total +341 over 10 weeks

    As you can see, Belviq over 10 weeks has out-paced Qsymia's refill growth. That is a fact. -SV

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARNA
4.64+0.34(+7.91%)Jun 30 4:00 PMEDT